Matt Pulisic
On February 3, 2025, the Company announced the appointment of Matt Pulisic as the Company’s Chief Financial Officer, effective as of January 30, 2025 (the “ Effective Date ”).
Highest-materiality recent filing
Genelux enters $100M at-the-market equity offering agreement with TD Cowen
Sales Agreement with TD Cowen allows offering of common stock up to $100M aggregate.
Genelux prices $20M public offering of 6.7M shares at $3.00
Priced underwritten public offering of 6,666,667 shares at $3.00 each.
Genelux reports 33% ORR in SCLC and 60% DCR in NSCLC with systemic Olvi-Vec
SCLC Phase 1b/2: 33% ORR (3/9 PRs), 67% DCR; highest dose cohort 67% ORR (2/3) with tumor shrinkage ~55% and ~85%.
Genelux reprices employee stock options to $3.33 from up to $22.40; covers 2.7M shares
Exercise price reduced to $3.33 for eligible options with prior range $6.00–$22.40 per share.
Genelux reports preliminary cash ~$30.9M; positive Olvi-Vec SCLC data and FDA guidance for PRROC
Preliminary cash, cash equivalents, and short-term investments as of Dec 31, 2024: ~$30.9M (unaudited).
Genelux prices $10.5M underwritten offering of 3M shares at $3.50/share
Gross proceeds of $10.5M from 3,000,000 shares at $3.50 per share; closing expected March 26, 2025.
Genelux CFO Lourie Zak resigns; Matt Pulisic appointed CFO with $410k salary, 275k option
Lourie Zak resigned as CFO effective Jan 29, 2025; separation includes $180k cash payment (6 months salary) and advisory role through Aug 29, 2025.
Genelux prices $27.5M offering of 6.875M shares and warrants at $4.00
Gross proceeds ~$27.5M; net ~$25.4M from 6,875,000 shares and 6,875,000 warrants at combined $4.00/unit.
On February 3, 2025, the Company announced the appointment of Matt Pulisic as the Company’s Chief Financial Officer, effective as of January 30, 2025 (the “ Effective Date ”).
On January 29, 2025 (the “ Separation Date ”), Lourie Zak resigned as Chief Financial Officer of Genelux Corporation (the “ Company ”), effective immediately.
On September 23, 2024, Caroline Jewett notified Genelux Corporation (the “Company”) of her resignation as Vice President, Head of Quality of the Company, effective as of October 18, 2024.
Max materiality 0.85 · Median 0.60 · Most common event other_material